"The right to live should never be contingent to the ability to pay. Medicines that are required the most should never be sold in a monopoly. It is a very sad part of the story that countries, who need the medicines the most, are the ones who can't afford them because of the high cost and the patent by foreign companies to prevent any other firms from manufacturing the same drugs at a low cost, he said."
New Delhi, May 3 - India can be a global leader in supplying affordable and high quality medicines to the world, and especially to the underdeveloped countries where such medicines do not reach the poor because of their high cost and the monopoly of foreign manufacturers, said a leading entrepreneur.

India has emerged as the pharmacy of the world, said Yousuf Hamied, chairman of pharmaceutical giant Cipla.

Hamied was speaking here Friday at the special screening of Fire in the Blood - a documentary that depicts mass devastation in Africa, Asia and other parts of the global South due to obstruction of low cost anti-retroviral drugs used for the treatment of HIV/AIDS.

The documentary was screened by the ministry of external affairs.

India is not just contributing to the arena of medicines but also playing a humanitarian role by manufacturing medicines and supplying them at a low cost across the world, he said.

India is supplying essential medicines to people in all corners of the world. It is a great role towards humanity and also an initiative to curb the monopoly over medicines created by multinational pharma companies, said Hamied.

The 59-minute documentary tells the story of how western pharmaceutical companies and governments blocked access to low cost AIDS drugs for the global South countries in 1996 and afterwards - leading to 10 million deaths.

The right to live should never be contingent to the ability to pay. Medicines that are required the most should never be sold in a monopoly. It is a very sad part of the story that countries, who need the medicines the most, are the ones who can't afford them because of the high cost and the patent by foreign companies to prevent any other firms from manufacturing the same drugs at a low cost, he said.

The companies having patent rights for medicines should allow other firms to manufacture the drugs and ask for royalty in return. Drugs manufacturing should never be seen as a money making business, especially when the motive is to save lives, Hamied added.


comments powered by Disqus
Read more on:
 INDIA (136901 views)
 DELHI (98261 views)
 MONEY (33095 views)
 GLOBAL (17901 views)
 AIDS (12085 views)
 BLOOD (11961 views)
 MINISTRY OF EXTERNAL AFFAIRS (6743 views)
 EXTERNAL AFFAIRS (6231 views)
 TREATMENT (6241 views)
 MILLION (6011 views)
 1996 (5451 views)
 AFRICA (5201 views)
 MEDICINE (4691 views)
 PHARMACEUTICAL COMPANIES (3910 views)
 DEVELOPED COUNTRIES (3041 views)
 UGS (2871 views)
 ENTREPRENEUR (2721 views)
 YOUSUF (2321 views)
 CIPLA (2021 views)
 

PERMALINK

http://www.nerve.in/news:2535002371538
You can quote the permanent link above for a direct link to the story. We do not archive or expire our news stories.


STORY OPTIONS
  Email this story to a friend
  XML feed for India


 
COPYRIGHTS INFORMATION
All rights reserved for news content. Reproduction, storage or redistribution of Nerve content and articles in any medium is strictly prohibited.
Contact Nerve Staff for any feedback, corrections and omissions in news stories.
 

All rights reserved for the news content. Reproduction, storage or redistribution of Nerve content and articles in any medium is strictly prohibited.